Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials.

Abstract

BACKGROUND:

The benefits of the application of basiliximab induction therapy in liver transplantation are not clear. The present meta-analysis was to evaluate the pros and cons of basiliximab use in liver transplantation.

DATA SOURCES:

We searched the associated publications in English from July 1998 to December 2015 in the following databases: MEDLINE, PubMed, Ovid, EMBASE, Web of Science and Cochrane Library.

RESULTS:

Basiliximab significantly decreased the incidence of de novo diabetes mellitus after liver transplantation (RR=0.56; 95% CI: 0.34-0.91; P=0.02). Subgroup analysis showed that basiliximab in combination with steroids-free immunosuppressant significantly decreased the incidence of biopsy-proven acute rejection (RR=0.62; 95% CI: 0.39-0.97; P=0.04) and new-onset hypertension (RR=0.62; 95% CI: 0.42-0.93; P=0.02).

CONCLUSIONS:

Basiliximab may be effective in reducing de novo diabetes mellitus. What is more, basiliximab in combination with steroids-free immunosuppressant shows statistical benefit to reduce biopsy-proven acute rejection and de novo hypertension.

• Authors: Guo-Qing Zhang, Cheng-Shuo Zhang, Ning Sun, Wu Lv, Bao-Min Chen, Jia-Lin Zhang
• Journal: Hepatobiliary & pancreatic diseases international : HBPD INT (Hepatobiliary Pancreat Dis Int) Vol. 16 Issue 2 Pg. 139-146 (Apr 2017) ISSN: 1499-3872 [Print] Singapore
• PMID: 28381376 (Publication Type: Journal Article, Meta-Analysis, Review)

Chemical References

• Antibodies, Monoclonal
• Immunosuppressive Agents
• Recombinant Fusion Proteins
• Basiliximab

Topics

• Adult
• Aged
• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Basiliximab
• Biopsy
• Chi-Square Distribution
• Diabetes Mellitus (etiology, prevention & control)
• Drug Therapy, Combination
• Female
• Graft Rejection (immunology, mortality, prevention & control)
• Graft Survival (drug effects)
• Humans
• Hypertension (etiology, prevention & control)
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Liver Transplantation (adverse effects, mortality)
• Male
• Middle Aged
• Odds Ratio
• Recombinant Fusion Proteins (adverse effects, therapeutic use)
• Risk Factors
• Treatment Outcome
• Young Adult